JNJ 63709178

Drug Profile

JNJ 63709178

Alternative Names: CD123 x CD3 DuoBody; CD123-CD3 DuoBody protein; CNTO 9958; JNJ-63709178

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Genmab; Janssen Research & Development
  • Developer Janssen Research & Development
  • Class Bispecific antibodies
  • Mechanism of Action CD3 antigen modulators; Interleukin 3 receptor alpha subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Acute myeloid leukaemia

Most Recent Events

  • 06 Dec 2016 Pharmacodynamic results from a preclinical study in Acute myeloid leukaemia reported at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 15 Sep 2016 Suspended - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA, Australia, Belgium, Germany (IV) (NCT02715011)
  • 01 Jun 2016 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA, Australia, Belgium, Germany (IV) (NCT02715011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top